China Resources Pharmaceutical Group Limited provided preliminary unaudited consolidated financial guidance for the year ended 31 December 2019. For the year, the Group expects that, during the Year, the Group's net profit (expressed in Renminbi) decreased by approximately 28%-33% as compared with the corresponding period last year despite the fact that the Group's total revenue for the Year maintained stable growth as compared with the corresponding period last year.